Alterity director files initial insider report

ALTERITY THERAPEUTICS LTD director Ann Michelle Cunningham has filed an initial Form 3 insider ownership report.

Rhea-AI Filing Summary

ALTERITY THERAPEUTICS LTD director Ann Michelle Cunningham has filed an initial Form 3 insider ownership report. The filing lists her as a director but shows no reported transactions or derivative positions, indicating this is a baseline disclosure of her status rather than an update to prior trading activity.

Key Terms

Form 3, issuerName, reportingPersons

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3): {...}"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

issuerName regulatory

""issuerName": "ALTERITY THERAPEUTICS LTD""

reportingPersons regulatory

""reportingPersons": [ { "name": "Cunningham Ann Michelle""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Ann Michelle Cunningham Form 3 for ATHE report?

The Form 3 for ATHE reports that Ann Michelle Cunningham is a director of Alterity Therapeutics Ltd. It shows no reported transactions or derivative holdings, serving as an initial baseline insider ownership filing.

Does the ATHE Form 3 show any shares bought or sold by Ann Michelle Cunningham?

No, the Form 3 for ATHE shows no reported transactions. All transaction counts and share amounts, including buys, sells, exercises, gifts, and tax withholdings, are listed as zero in the summary data.

What insider role does Ann Michelle Cunningham hold at Alterity Therapeutics (ATHE)?

The filing identifies Ann Michelle Cunningham as a director of Alterity Therapeutics Ltd. She is not listed as an officer or ten percent owner in this Form 3, which focuses on her status for insider reporting purposes.

Does the ATHE Form 3 disclose any derivative securities for Ann Michelle Cunningham?

No, the Form 3 derivative summary for ATHE is empty. It lists zero derivative transactions and shows no remaining derivative positions, meaning no options, warrants, or similar instruments are reported in this filing.

What is the net buy or sell direction in Ann Michelle Cunningham’s ATHE Form 3?

The transaction summary in the ATHE Form 3 shows a neutral net buy/sell direction. Buy, sell, and exercise share counts are all zero, so there is no net change from reported trading activity in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 08:05 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cunningham Ann Michelle

(Last) (First) (Middle)

255 N CALDWELL CIRCLE

(Street)

DOWNINGTOWN PENNSYLVANIA 19335

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/17/2026

3. Issuer Name and Ticker or Trading Symbol
ALTERITY THERAPEUTICS LTD [ ATHE ]

3a. Foreign Trading Symbol
[ATH.ASX]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	Ann Michelle Cunningham	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)